TherapeuticsMD Presented New Research at the American College of Obstetricians & Gynecologists 2019 Annual Meeting that Explo...
May 06 2019 - 7:00AM
Business Wire
Large Survey Exclusively Focused on Women’s
Male Partners Reveals a Clear Negative Impact of Menopause on
Relationships, Lack of Clarity About Symptoms and Treatments, and
Men’s Willingness to Discuss and Influence Decisions
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading
women's healthcare company, today announced the presentation of
results from the Men’s Attitude Toward Menopause Survey (MATE), a
large study of men’s understanding of and attitudes related to
menopause, at the American College of Obstetricians and
Gynecologists 2019 Annual Meeting. The data, representing insights
collected from 450 men married to and living with women of
menopausal age, uncovered men’s perceptions and attitudes towards
menopause and their role in their partner’s menopausal
transition.
The MATE survey showed that while men are sensitive to the
changes experienced by women during their menopause transition and
believe those changes have a negative impact on their
relationships, they are less aware of the specific menopausal
symptoms or opportunities available for women to get relief from
symptoms.
When presented with a list of symptoms that their female
partners might be facing, more than half (54%) recognized that
their partner was experiencing sleeplessness or difficulty
sleeping. Additionally, nearly half reported that their partner was
living with a lack of energy (49%), loss of desire for sexual
contact (48%), mood swings (47%) and hot flashes (46%). When
prompted to select an option, only 55% attributed these symptoms to
menopause.
Sixty-three percent of respondents believed their partner’s
symptoms had personally affected them with 77% believing the impact
was negative to themselves and their relationships (56%). These men
acknowledged that symptoms of menopause had a great or negative
impact on their partners as it pertained to love making (65%), mood
swings (63%) and romance (58%). Some men noted that it was
upsetting or frustrating to see their partners going through this
transition; however, less than half of respondents were aware that
there are treatment options for menopausal symptoms.
“TherapeuticsMD recognizes that menopause is not only a
life-transitioning event for women, but also for the men in their
lives,” said TherapeuticsMD Chief Medical
Officer Sebastian Mirkin. “The MATE survey reveals an
opportunity to make that transition easier by helping men better
understand symptoms and potential solutions to support their
partners in the management of their menopausal symptoms.”
The presentation will be made available on the Investors &
Media section of the company’s website at
www.therapeuticsmd.com.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The company is
committed to advancing the health of women and championing
awareness of their healthcare issues. To learn more about
TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on
Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that the company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as “believes,” “hopes,”
“may,” “anticipates,” “should,” “intends,” “plans,” “will,”
“expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled “Risk Factors” in
the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K
and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K,
and include the following: the company’s ability to maintain or
increase sales of its products; the company’s ability to develop
and commercialize IMVEXXY®, ANNOVERA™, BIJUVA™ and its hormone
therapy drug candidates and obtain additional financing necessary
therefor; whether the company will be able to comply with the
covenants and conditions under its term loan facility; the
potential of adverse side effects or other safety risks that could
adversely affect the commercialization of the company’s current or
future approved products or preclude the approval of the company’s
future drug candidates; the length, cost and uncertain results of
future clinical trials; the company’s reliance on third parties to
conduct its manufacturing, research and development and clinical
trials; the availability of reimbursement from government
authorities and health insurance companies for the company’s
products; the impact of product liability lawsuits; the influence
of extensive and costly government regulation; the volatility of
the trading price of the company’s common stock and the
concentration of power in its stock ownership. PDF copies of the
company’s historical press releases and financial tables can be
viewed and downloaded at its
website: www.therapeuticsmd.com/pressreleases.aspx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190506005087/en/
Investor ContactNichol
OchsnerVice President, Investor Relations561-961-1900, ext.
2088Nochsner@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024